Back
ESC Premium Access

Adverse event profiles after brand or generic clopidogrel in the Food and Drug Administration Adverse Event Reporting System (FAERS)

Session: Safety issues with anti-platelets drugs
Topic: Antiplatelet Drugs
Speaker: Associate Professor V. Serebruany (Baltimore, US)
Event: ESC Congress 2018

Congress Presentation

About the speaker

Associate Professor Victor L Serebruany

Johns Hopkins University of Baltimore, Baltimore (United States of America)
2 presentations
0 follower

3 more presentations in this session

Perceived or calculated bleeding risk in patients undergoing percutaneous coronary intervention: inside the post-pci prospective registry

Speaker: Doctor M. Ferlini (Pavia, IT)

Access
Abstract
Thumbnail

Are perceived or calculated bleeding risk related to dapt choice in patients undergoing percutaneous coronary intervention?

Speaker: Doctor M. Ferlini (Pavia, IT)

Access
Abstract
Thumbnail

Platelet inhibition on brand and generic clopidogrel chronic therapy

Speaker: Doctor A. Soliman (Dammam, SA)

Access
Abstract
Slides
Video
Thumbnail

Access the full session

Safety issues with anti-platelets drugs

Speakers: Associate Professor V. Serebruany, Doctor M. Ferlini, Doctor M. Ferlini, Doctor A. Soliman
Access
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb